UNIVERSITY OF CALIFORNIA – LOS ANGELES HEALTH SCIENCES Researchers at the UCLA Jonsson Comprehensive Cancer Center have confirmed that a large number of genetic variants of unknown significance are in fact verified mutations that predispose patients to a rare hereditary syndrome that increases the risk of kidney cancer. By functionally characterizing the behavior of these mutations, researchers and...
Tag: <span>kidney cancer</span>
Post
Researchers ID biomarkers of response to immunotherapy for kidney cancer
by Johns Hopkins University School of Medicine Pathologists look through a microscope to evaluate H&E slides for tumor infiltrating immune cells and necrosis in patients with kidney cancer who go on to receive immunotherapy. Credit: Julie Stein Deutsch via Biorender The number of immune cells in and around kidney tumors, the amount of dead cancer...
Post
Combination therapy a promising option for advanced kidney cancer patients already treated with immunotherapy
by Dana-Farber Cancer Institute Credit: Unsplash/CC0 Public Domain Immunotherapies, such as anti-PD-1 and anti-PD-L1, have become standard first line therapies for patients with advanced renal cell carcinoma (kidney cancer). Most patients, however, eventually experience disease progression, with no consensus on what therapy to use next. In an open-label phase 2 study, led by Dana-Farber Cancer...
Post
Gene signature points to prognosis in kidney cancer
KAROLINSKA INSTITUTET Among patients with kidney cancer, the activity of four specific genes in the cancer cells seems to be able to predict the risk of the tumour spreading and the patient’s chances of survival. This is shown by researchers from Karolinska Institutet in Sweden in a preclinical study published in Nature Communications. “This could potentially...
Post
Deliberately damaging DNA could boost the effectiveness of immunotherapy in kidney cancer
by Institute of Cancer Research Cancer cell being attacked by two immune cells. Credit: NIH Image Gallery, CC BY 2.0 DNA damage is one of the foundational causes of cancer. But researchers have now found that deliberately causing DNA damage—by delivering additional treatments like radiotherapy—could improve the effectiveness of immunotherapy for some people with kidney...
Post
Three-drug combination slows progression of advanced kidney cancer
by Dana-Farber Cancer Institute Credit: CC0 Public Domain A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute. “Patients who received the kinase inhibitor cabozantinib in addition to checkpoint-blockers nivolumab and ipilimumab experienced...
Post
Can kidney cancer be mistaken for kidney stones?
Kidney cancer shares some similar symptoms with kidney stones, including blood in the urine, lower back pain, and fatigue. Due to these similarities, some medical professionals may incorrectly diagnose kidney cancer as kidney stones. Kidney cancer is one of the 10 most common cancers in people. Kidney cancer shares some symptoms with kidney stones, which...
Post
Belzutifan induced strong responses in patients with von Hippel-Lindau disease-associated kidney cancer
HOUSTON ― Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center showed that treatment with belzutifan, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, achieved strong clinical activity in patients with renal cell carcinomas (RCC) and non-renal cell carcinoma neoplasms associated with von Hippel-Lindau (VHL) disease. The study was published...
Post
Targeted drug shows activity against brain metastases in kidney cancer
by Dana-Farber Cancer Institute A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need. The drug, cabozantinib, is a tyrosine kinase inhibitor that attacks several targets in cancer cells....
Post
New use of old drug reduces risk of kidney cancer returning
by European Association of Urology Credit: CC0 Public Domain Using an existing drug for late-stage kidney cancer at an earlier stage of the disease could reduce the risk of cancer recurring by a third, according to new research. The findings from the Phase III trial are presented today at the European Association of Urology Congress (EAU21). There...